A new drug for intraoperative fluorescence imaging has been registered
Mirpharm announces successful registration of Indocyanine Green (ICG), an effective and affordable drug for fluorescent imaging during surgery
Moscow, October 2022
Mirpharm has successfully completed the registration of a new drug, Indocyanine Green (ICG).
Indocyanine green (ICG) is the most effective and affordable drug for in vivo fluorescent navigation in surgery and oncology.
The advantages of using ICG are:
● proven effectiveness in surgery (it is in practical use since 1957)
● does not recirculate in the body; does not interact with other drugs
● no cumulation or interference
● wide tolerated dosing range (200-fold) from 0.25 mg to 50 mg (2 fls)
● excreted exclusively via the liver (bile ducts, gallbladder, then intestines)
● steadily short elimination half-life — 3-4 minutes
● is bound to plasma proteins during intravenous administration; it is rapidly and evenly distributed in the vascular system
● imaging equipment does not require stationary installation (it is portable)
Domestic ICG:
● a significantly lower content of impurities
● 25% cheaper
● packaging № 1, 5, 10 (a rival has only № 5)
● double quality control
● guaranteed absence of defects in finished pharmaceutical products (FPP), a full production cycle in Russia, including the synthesis of the substance
Mirpharm is an international group of companies with its own R&D centers and production facilities in Russia and the European Union.
Note:
The press release contains information about prescription drugs. The use of this information for the preparation of publications should be carried out in accordance with the legislation of the Russian Federation on advertising (including, but not limited to, Article 24 of the Federal Law of March 13, 2006 № 38-FL “Advertising Law"), according to which, in particular , advertising of medicines dispensed by prescription of a doctor is allowed only at the venues of medical or pharmaceutical exhibitions, seminars, conferences and other similar events, as well as in specialized printed publications intended for medical and pharmaceutical workers. Failure to comply with these requirements (namely, the mention of the name of the drug, the placement of the image of the package or its elements in the media that are not related to specialized printed publications intended for medical and pharmaceutical workers) entails administrative liability.